ARCHIVES

Bad News for EPO Products Brings FDA Scrutiny, Payment Curbs. FDA Issues Alert to Doctors.

This article is from The Cancer Letter archive.

Vol. 33 No. 07 | February 23, 2007

Download PDF Visit The Full Archive

Related Articles

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

In Brief: Pediatric Groups Endorse Merger Plan; NCI Charters Consumer Liaison Group

November 13, 1998

Award Fees Show House NCI thinks FCRF Contractors Are Performing

August 15, 1986

More Breast Cancer Patients Opt To Remove Both Breasts

November 26, 2010

NCI-Approved Clinical Trials

August 31, 2001

Fisher, Hallman Lecture At annual ASCO/AACR Meeting

May 9, 1980